PDF(Pubmed)
Abstract：
Immune checkpoint blockades (ICBs) have revolutionized cancer therapy through unleashing anti-tumor adaptive immunity. Despite that, they are usually effective only in a small subset of patients and relapse can occur in patients who initially respond to the treatment. Recent breakthroughs in this field have identified innate immune checkpoints harnessed by cancer cells to escape immunosurveillance from innate immunity. MHC1 appears to be such a molecule expressed on cancer cells which can transmit a negative signal to innate immune cells through interaction with leukocyte immunoglobulin like receptor B1 (LILRB1). The review aims to summarize the current understanding of MHC1/LILRB1 axis on mediating cancer immune evasion with an emphasis on the therapeutic potential to block this axis for cancer therapy. Nevertheless, one should note that this field is still in its infancy and more studies are warranted to further verify the effectiveness and safety in clinical as well as the potential to combine with existing immune checkpoints.
摘要：
免疫检查点阻断（ICBs）通过释放抗肿瘤适应性免疫，彻底改变了癌症治疗。尽管如此,它们通常仅在一小部分患者中有效，并且最初对治疗有反应的患者可能会复发。该领域的最新突破已经确定了由癌细胞利用的先天免疫检查点以逃避先天免疫的免疫监视。MHC1似乎是在癌细胞上表达的分子,其可以通过与白细胞免疫球蛋白样受体B1(LILRB1)的相互作用向先天免疫细胞传递阴性信号。该综述旨在总结目前对MHC1/LILRB1轴在介导癌症免疫逃避方面的理解，并强调阻断该轴用于癌症治疗的治疗潜力。然而，应该注意的是,该领域仍处于起步阶段,需要更多的研究来进一步验证临床的有效性和安全性,以及与现有免疫检查点联合使用的可能性.
